scholarly journals GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

2021 ◽  
Vol 17 (8) ◽  
pp. 2050-2068
Author(s):  
Xiaoxuan Ma ◽  
Zhenghong Liu ◽  
Iqra Ilyas ◽  
Peter J. Little ◽  
Danielle Kamato ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Receptor Agonists ◽  
Cardiovascular Actions

Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential

Physiology ◽  
2005 ◽  
Vol 20 (5) ◽  
pp. 357-365 ◽  
Author(s):  
Elaine M Sinclair ◽  
Daniel J. Drucker
Keyword(s):  
Type 2 Diabetes ◽  
Human Disease ◽  
Clinical Relevance ◽  
Therapeutic Potential ◽  
Mechanisms Of Action ◽  
Receptor Antagonists ◽  
Glucagon Receptor ◽  
Receptor Agonists ◽  
Glucagon Like Peptide

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.

scholarly journals Therapeutic potential of nuclear receptor agonists in Alzheimer’s disease

2017 ◽  
Vol 58 (10) ◽  
pp. 1937-1949 ◽  
Author(s):  
Miguel Moutinho ◽  
Gary E. Landreth
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nuclear Receptor ◽  
Therapeutic Potential ◽  
Receptor Agonists

scholarly journals How glucagon-like peptide 1 receptor agonists work

2021 ◽  
Author(s):  
Christine Rode Andreasen ◽  
Andreas Andersen ◽  
Filip Krag Knop ◽  
Tina Vilsbøll
Keyword(s):  
Body Weight ◽  
Therapeutic Potential ◽  
Clinical Effects ◽  
Glucose Lowering ◽  
Receptor Agonists ◽  
Reduce Body Weight ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Clinical Utilisation

Recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of actions, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.

Cardiovascular actions and therapeutic potential of tanshinone IIA

2012 ◽  
Vol 220 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Si Gao ◽  
Zhiping Liu ◽  
Hong Li ◽  
Peter J. Little ◽  
Peiqing Liu ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Tanshinone Iia ◽  
Cardiovascular Actions

scholarly journals Elucidating GABAB and GABAB Receptor Functions in Anxiety Using the Stress-Induced Hyperthermia Paradigm: A Review

2010 ◽  
Vol 4 (1) ◽  
pp. 1-14 ◽  
Author(s):  
Christiaan H. Vinkers ◽  
John F. Cryan ◽  
Berend Olivier ◽  
Lucianne Groenink
Keyword(s):  
Stress Response ◽  
Emotional Disorders ◽  
Gaba Receptor ◽  
Acute Stress ◽  
Gabab Receptor ◽  
Therapeutic Potential ◽  
Core Body Temperature ◽  
Induced Hyperthermia ◽  
Receptor Agonists ◽  
Anxiolytic Drugs

Exposure to acute psychological or physical stress increases core body temperature (stress-induced hyperthermia, SIH) which is part of the autonomic stress response. SIH is used as a putative rodent anxiety paradigm in which anxiolytic drugs reduce the SIH response. The predictive validity of the SIH paradigm has proven to be good, making it suitable to detect the putative anxiolytic properties of drugs. So far, GABA receptor agonists including benzodiazepines and hypnotics have proven to attenuate the SIH response. The GABAA receptor has been known to be closely involved in the acute stress response. Also, the recent development of compounds with selective efficacy for different subunits at the benzodiazepine site of the GABAA receptor has renewed interest for the therapeutic potential of GAB ergic drugs. Moreover, metabotropic (GABAB) receptor agonists reduce the SIH response. GABAB receptors are ubiquitously expressed in the central nervous system, and there is evidence for a role of the GABAB receptor in anxiety. Thus, both drugs acting on the GABAA and the GABAB receptor are generally able to attenuate the SIH response, and this review presents a detailed overview of the effects of both drug classes on the SIH response. As the GABA receptor family is diverse and complex, this paradigm may contribute to the elucidation of the putative effects of GABA ergic drugs in emotional disorders such as anxiety and depression

scholarly journals Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation

2020 ◽  
Vol 21 (4) ◽  
pp. 431-447
Author(s):  
Han Xie ◽  
Natesh Yepuri ◽  
Qinghe Meng ◽  
Ravi Dhawan ◽  
Colin A. Leech ◽  
...  
Keyword(s):  
Acetylcholine Receptor ◽  
Nicotinic Acetylcholine Receptor ◽  
Therapeutic Potential ◽  
Α7 Nicotinic Acetylcholine Receptor ◽  
Nicotinic Acetylcholine ◽  
Receptor Agonists

scholarly journals 5-HT4 receptor agonists and antagonists: Their effects on gastrointestinal function and therapeutic potential

2000 ◽  
Vol 82 ◽  
pp. 37
Author(s):  
Yukinori Naaakura ◽  
Shinobu Akuzawa ◽  
Yuki Naitoh ◽  
Hiroyuki Ito ◽  
Tokio Yamaguchi ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Gastrointestinal Function ◽  
Receptor Agonists ◽  
Receptor Agonists And Antagonists

scholarly journals The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse Liability

2012 ◽  
Vol 4 (2) ◽  
pp. 214-224 ◽  
Author(s):  
Ann P. Lin ◽  
Mei-Chuan Ko
Keyword(s):  
Therapeutic Potential ◽  
Abuse Liability ◽  
Orphanin Fq ◽  
Receptor Agonists
Sign in / Sign up

Export Citation Format

Share Document